Adaptive Biotechnologies Corporation, a leading commercial-stage biotech firm, has made strides in developing an advanced immune medicine platform to aid in the diagnosis and treatment of diseases. The firm's immunoSEQ platform is an innovative immunosequencing product used by researchers to uncover new diagnostic signals and address complex translational issues. Additionally, Adaptive Biotechnologies offers clonoSEQ, an advanced clinical diagnostic product for the monitoring of minimal residual diseases in patients diagnosed with chronic lymphocytic leukemia, multiple myeloma, and B cell acute lymphoblastic leukemia. The firm specializes in the diagnosing, monitoring, and treatment of diverse diseases involving cancer and autoimmune disorders. As pioneers in the field, Adaptive Biotechnologies offers life sciences research, clinical diagnostic, and drug discovery applications for various therapeutic areas. The company has entered into strategic partnerships with esteemed firms, like Genentech, to develop cutting-edge neoantigen-directed T cell therapies for various cancers, and Microsoft, a partnership focused on further diagnosis through diagnostic tests for blood tests. Adaptive Biotechnologies Corporation was initially called Adaptive TCR Corporation until 2011, when it rebranded. The company has its headquarters in Seattle, Washington, and was incorporated in 2009.
Adaptive Biotechnologies's ticker is ADPT
The company's shares trade on the NASDAQ stock exchange
They are based in Seattle, Washington
There are 501-1000 employees working at Adaptive Biotechnologies
It is adaptivebiotech.com
Adaptive Biotechnologies is in the Healthcare sector
Adaptive Biotechnologies is in the Biotechnology industry
The following five companies are Adaptive Biotechnologies's industry peers: